Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-monkeys

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 24, Issue 4, 2000, Pages 607-617

  Goulet, Martin ^a   Grondin, Richard ^a   Morissette, Marc ^a   Maltais, Stéphane ^a   Falardeau, Pierre ^a   Bédard, Paul J ^a   Di Paolo, Thérèse ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Binding autoradiography; Cabergoline; D1 and D2 receptors; In situ hybridization; MPTP monkeys; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CABERGOLINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; DRUG TOLERANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN SITU HYBRIDIZATION; MONKEY; NONHUMAN; PARKINSON DISEASE; RECEPTOR BINDING; STEADY STATE;

ANIMALS; ANTIPARKINSON AGENTS; BINDING SITES; DISEASE MODELS, ANIMAL; ERGOLINES; FEMALE; IN SITU HYBRIDIZATION; MACACA FASCICULARIS; PARKINSON DISEASE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 0034190598     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(00)00096-8     Document Type: Article

References (24)

1. Alexander GM, Brainard L, Gordon SW, Hichens M, Grothusen JR and Schwartzman RJ (1991) Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates. Brain Res 547: 181-189.
2. Alexander GM, Schwartzman RJ, Grothusen JR, Brainard L and Gordon SW (1993) Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment. Brain Res 625: 276-282.
3. 2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 272: 854-859.
4. A receptors in the striatopallidal complex. Brain Res 680: 43-52.
5. Chen JF, Aloyo VJ and Weiss B (1993) Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Neuroscience 54: 669-680.
6. Chen JF, Qin ZH, Szele F, Bai G and Weiss B (1991) Neuronal localization and modulation of the D2 dopamine receptor mRNA in brain of normal mice and mice lesioned with 6-hydroxydopamine. Neuropharmacology 30: 927-941.
7. Clark AJL, Ishii S, Richert N, Merlino GT and Pastan I (1985) Epidermal growth factor regulates the expression of its own receptor. Proc Natl Acad Sci USA 86: 8374-8878.
8. Coirini H, Schumacher M, Angulo JA and McEwen BS (1990) Increase in striatal dopamine D2 receptor mRNA after lesions or haloperidol treatment. Eur J Pharmacol 186: 369-371.
9. Di Paolo T, Bédard PJ, Daigle M and Boucher R (1986) Long-term effects of MPTP on central and peripheral catecholamine and indolamine concentrations in monkeys. Brain Res 379: 286-293.
10. Falardeau P, Bédard PJ and Di Paolo T (1988) Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys. Neurosci Lett 86: 225-229.
11. Gagnon C, Bédard PJ and Di Paolo T (1990) Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur J Pharmacol 178: 115-120.
12. Gagnon C, Gomez-Mancilla B, Markstein R, Bédard PJ and Di Paolo T (1995) Effect of adding the D1 agonist CY208243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors. Prog Neuro-Psychopharmacol & Biol Psychiat 19: 667-676.
13. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ and Sibley DR (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250: 1429-1432.
14. Goss JR, Kelly AB, Johnson SA and Morgan DG (1991) Haloperidol treatment increases D2 dopamine receptor protein independently of RNA levels in mice. Life Sci. 48: 1015-1022.
15. Goulet M, Morissette M, Calon F, Blanchet PJ, Falardeau P, Bédard PJ and Di Paolo T (1997) Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis. Neuroscience 79: 497-507.
16. Graham WC, Sambrook MA and Crossman AR (1993) Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res 602: 290-303.
17. Grondin R, Goulet M, Di Paolo T and Bédard PJ (1996) Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Brain Res 735: 298-306.
18. Morissette M, Goulet M, Calon F, Falardeau P, Blanchet PJ, Bédard PJ and Di Paolo T (1996) Changes of D1 and D2 dopamine receptor mRNA in the brain of ḾPTP monkeys: Correction with chronic administration of L-DOPA. Mol Pharmacol 50: 1073-1079.
19. Parent A and Hazrati L-N (1995) Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Rev 20: 91-127.
20. Qian Y, Hitzemann B, Yount GL, White JD and Hitzemann R (1993) D1 and D2 dopamine receptor turnover and D2 messenger RNA levels in the neuroleptic-responsive and the neuroleptic nonresponsive lines of mice. J Pharmacol Exp Ther 267: 1582-1590.
21. Szabo J and Cowan WM (1984) A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis). J Comp Neurol 222: 265-300.
22. Weiss B, Zhou L-W, Chen JF, Szele F and Bai G (1990) Distribution and modulation of the D2 dopamine receptor mRNA in mouse brain: Molecular and behavioral correlates. Adv Biosci 77: 9-25.
23. Willeman T, Harding C and Stahl P (1985) Receptor-mediated endocytosis. Biochem J 232: 1-14.
24. Zhou LW, Qin ZH and Weiss B (1991) Downregulation of stereotyped behavior and production of latent locomotor behaviors in mice treated continuously with quinpirole. Neuropsychopharmacology 4: 47-55.